Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects:

Mod loss is associated with a reduction of central brain NBs. by Amalia S. Parra (4173004)

Subjects:

HFD decreases intermediate-term memory. by Tong Yue (6033305)

“…<p>(A) The survival rate of 10d <i>Canton-S</i> fed with ND or HFD was observed for 7 days. There was no significant decline in the survival rate in flies fed with HFD compared with ND (n = 10 vials, containing 20 flies at each time point). …”

Cephalometric measurement points. by Lijuan Liu (136685)

Subjects:

The small blue circles show the IC-volume (mean of left and right) from 72 males and the small red squares from 51 females as a function of age. by Pingling Kwok (14896191)

Subjects:

Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations. by Denis Mustafov (19137870)

“…<p><b>(A)</b> A significant reduction in colony-forming ability was observed in U87MG cells treated with 100ΜM SHG-44 compared to 100ΜM cis-platin and the untreated control. …”

Loss of <i>Rab23</i> decreases ciliation in MEFs and Tbr1 + intermediate progenitors. by Wan Ying Leong (22075947)

Localization of MTT reduction (formazan) in human spermatozoa. by Rim Kooli (15426816)

Subjects:

Comparison of PCNA expression grades across different groups at various time points. by Jian-feng Li (8667645)

Subjects:

Comparison of mTOR expression grading among different groups at different time points. by Jian-feng Li (8667645)

Subjects:

Comparison of renal tissue pathological damage grades across different groups at all time points. by Jian-feng Li (8667645)

Subjects:

EGFR/ERK signaling activity decreases throughout LEC elimination with endocytic activity dependency. by Kevin Yuswan (19845885)

Patient demographic information at four time points. by Ruitian Song (11045127)

Subjects:

Innovation and night light in large and small cities. by Saul Estrin (8629173)

The Laboratory Animal Flow Diagram. by Xueqin lu (22250795)

Subjects:

Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). by Xueqin lu (22250795)

Subjects:

General procedure for the synthesis of B. by Xueqin lu (22250795)

Subjects:

The trends of gene expression in the metabolism of triglycerides in liver tissue. by Xueqin lu (22250795)

Subjects:

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. by Xueqin lu (22250795)

Subjects:

The trends of cholesterol metabolism-related gene expression in liver tissue. by Xueqin lu (22250795)

Subjects: